Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director
Cannabis Law Report
JANUARY 4, 2022
AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. NYSE: AMAM), a position he previously held from 2010 through 2015. We are currently focused on developing the first FDA-approved therapy for emergency department physicians to treat the serious and sometimes fatal effects of cannabinoid intoxication.
Let's personalize your content